SCHEMBL3553014

SCHEMBL3553014

COC(=O)c1ccc(N2CCN(c3ccc(-c4ccccc4)cc3)C2=O)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.52
ALDH1A1 P00352 4/20 0.52
KDM4E B2RXH2 1/20 0.52
PKM P14618 1/20 0.52
HPGD P15428 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
CTSG P08311 1/20 0.52
CMA1 P23946 1/20 0.52
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
TSHR P16473 1/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
PTPN1 P18031 1/20 0.50
PDCD1 Q15116 1/20 0.49
CD274 Q9NZQ7 1/20 0.49
ALDH1A3 P47895 1/20 0.48
OPRM1 P35372 1/20 0.47
OPRL1 P41146 1/20 0.47
SCN1A P35498 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3559417 0.85 HDAC1 (0.51) ALDH1A1CTSGCMA1NPC1RAB9A
SCHEMBL1105491 0.81 TSHR (0.75) EGFRALDH1A1KDM4EPKMHPGD
SCHEMBL3552039 0.80 CA1 (0.50) EGFRALDH1A1KDM4ECTSGCMA1
SCHEMBL13006962 0.80 ALDH1A1 (0.56) ALDH1A1KDM4EHPGDCTSGCMA1
Phosphine SCHEMBL28496548 0.79 TSHR (0.72) EGFRALDH1A1KDM4EPKMHPGD
Phosphine SCHEMBL28493400 0.79 TSHR (0.72) EGFRALDH1A1KDM4EPKMHPGD
SCHEMBL3551549 0.79 CTSG (0.46) ALDH1A1HPGDCTSGCMA1NPC1
SCHEMBL14423199 0.79 CTSG (0.46) ALDH1A1HPGDCTSGCMA1NPC1
SCHEMBL3554080 0.79 CTSG (0.46) ALDH1A1HPGDCTSGCMA1NPC1
SCHEMBL14686979 0.78 ALDH1A1 (0.48) ALDH1A1HPGDCTSGCMA1OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100317649-A1 S1P Receptor Modulating Compounds and Use Thereof EPIX PHARMACEUTICALS, INC. (US) 2010-12-16 US disclosed
US-20100317649-A1 S1P Receptor Modulating Compounds and Use Thereof EPIX PHARMACEUTICALS, INC. (US) 2010-12-16 US disclosed
US-20100317649-A1 S1P Receptor Modulating Compounds and Use Thereof EPIX PHARMACEUTICALS, INC. (US) 2010-12-16 US disclosed
US-7790707-B2 S1P receptor modulating compounds and use thereof EPIX PHARMACEUTICALS INC. (US) 2010-09-07 US disclosed
US-7790707-B2 S1P receptor modulating compounds and use thereof EPIX PHARMACEUTICALS INC. (US) 2010-09-07 US disclosed
US-7790707-B2 S1P receptor modulating compounds and use thereof EPIX PHARMACEUTICALS INC. (US) 2010-09-07 US disclosed
EP-2010524-A2 S1P RECEPTOR MODULATING COMPOUNDS Epix Delaware, Inc. (US) 2009-01-07 EP disclosed
US-20080015177-A1 S1P receptor modulating compounds and use thereof AMGEN INC. 2008-01-17 US disclosed
US-20080015177-A1 S1P receptor modulating compounds and use thereof AMGEN INC. 2008-01-17 US disclosed
US-20080015177-A1 S1P receptor modulating compounds and use thereof AMGEN INC. 2008-01-17 US disclosed
WO-2007109330-A2 S1P RECEPTOR MODULATING COMPOUNDS EPIX DELAWARE, INC. (US) 2007-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015177-A1 S1P receptor modulating compounds and use thereof S1PR1, S1PR2, S1PR5 EGFR 2154/4885ALDH1A1 3180/4885KDM4E 1569/4885
US-20100317649-A1 S1P Receptor Modulating Compounds and Use Thereof S1PR1, S1PR2, S1PR5 EGFR 2154/4885ALDH1A1 3180/4885KDM4E 1569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.